An XRF study of trace elements accumulation in kidneys of tumor-bearing mice after treatment with cis-DDP with and without selenite and selenocistamine.
The effect of cis-DDP treatment with and without selenite and selenocistamine was studied on kidneys of tumor-bearing mice. The amounts of cis-DDP, selenite, and selenocistamine injected were chosen so as to be compatible with the treatment of humans. The animals were sacrificed at 7, 14, and 28 d after treatment. The kidneys were removed and subjected to trace element analysis by a novel X-ray fluorescence (XRF) method and for pathological assessment. The results show that following treatment with cis-DDP, K, Fe, Cu, and Zn reach a maximum level after 7 d; K, Fe, and Cu levels were significantly reduced by the addition of selenite. The level of Zn was reduced only in groups treated with selenite whereas that of K and Cu was reduced also in groups treated with selenocistamine with and without cis-DDP. The greatest increase in Pt and Se levels was reached 1 wk after injection with cis-DDP, with and without selenocompounds, and in the case of Pt was partly reduced by addition of selenite. Se returned to control values 2 wk after injection, although Pt was still high in all groups 2 and 4 wk after injection. The results corroborate the findings of our previous studies. The effect of selenocistamine in cis-DDP treated mice was partly insufficient. The pathological examination of the kidneys did not show any differences in the effect of various additives during the study.
Shenberg
C
C
Soreq Nuclear Research Centre, Yavne, Israel.
Boazi
M
M
Cohen
J
J
Klein
A
A
Kojler
M
M
Nyska
A
A
D000818:Animals; D002945:Cisplatin / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D003300:Copper / Q000378:metabolism; D003538:Cystamine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D004195:Disease Models, Animal; D006801:Humans; D007501:Iron / Q000378:metabolism; D007668:Kidney / Q000187:drug effects* / Q000378:metabolism; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009374:Neoplasms, Experimental / Q000188:drug therapy / Q000378:metabolism*; D016566:Organoselenium Compounds / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D011188:Potassium / Q000378:metabolism; D018038:Sodium Selenite / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D013052:Spectrometry, X-Ray Emission; D014131:Trace Elements / Q000378:metabolism*
D016566:Organoselenium Compounds; D014131:Trace Elements; C014807:selenocystamine; D003300:Copper; D007501:Iron; D018038:Sodium Selenite; D002945:Cisplatin; D003538:Cystamine; D011188:Potassium